Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) quinidine (HOS-085593) fusidic acid (HOS-086146) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) bepridil (HOS-085612) dronedarone (HOS-086144) alfuzosin (HOS-086139) lead (HOS-085592) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610) quinidine (HOS-085593) fusidic acid (HOS-086146) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) encainide (HOS-086145) flecainide (HOS-086203) propafenone (HOS-084530)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 16
HOS-086253 · Präparat HOS-083284
Antihistamines
Astemizole, terfenadine Ritonavir co-administration is likely to result in increased plasma concentrations of
astemizole and terfenadine and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 1f48833d034d82e8850a93103fb0059a535dd432c86bb3d9b79f981fbe9cbd89 · Zeichen 28042–28303 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-086441 · Präparat HOS-083284
Antihistamines
Astemizole, terfenadine Ritonavir co-administration is likely to result in increased plasma concentrations of
astemizole and terfenadine and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 1f48833d034d82e8850a93103fb0059a535dd432c86bb3d9b79f981fbe9cbd89 · Zeichen 29048–29309 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 5
HOS-108791 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and
during the ramp-up phase (see section
4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from this
agent (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) alfuzosin (HOS-086139) lead (HOS-085592) ranolazine (HOS-086141) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 3af5f7da19ec49492414676af6b40d10b1389f87518dc00840ff964623d97870 · Zeichen 617–4755 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 42–43
HOS-108988 · Präparat HOS-093083
42
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from
this agent (see section 4.5).
Quetiapine Increased plasma concentrations of
quetiapine which may lead to coma.
The concomitant administration with
quetiapine is contraindicated (see
section 4.5).
Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of
ergotamine, methylergonovine ergot derivatives leading to acute ergot
toxicity, including vasospasm and
ischaemia (see section 4.5).
GI motility agent Cisapride Increased plasma concentrations of
cisapride. Thereby, increasing the risk
of serious arrhythmias from this agent
(see section 4.5).
Hepatitis C virus Elbasvir/grazoprevir Increased risk of alanine transaminase
direct acting antivirals (ALT) elevations (see section 4.5).
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): hepatitis C virus (HOS-108813) elbasvir (HOS-108814) grazoprevir (HOS-108815) alanine (HOS-088949) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) lead (HOS-085592) ergot alkaloids (HOS-108807) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 513868d9cbc220f8b16283ba405e7ae3a7eba9be191b93bb320faa5cdf17028c · Zeichen 3976–6635 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 77–78
HOS-109062 · Präparat HOS-093083
77
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and during
the ramp-up phase (see section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious arrhythmias
from these agents (see section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or
other serious adverse effects from this
agent (see section 4.5).
Quetiapine Increased plasma concentrations of
quetiapine which may lead to coma. The
concomitant administration with
quetiapine is contraindicated (see section
4.5).
Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of ergot
ergotamine, methylergonovine derivatives leading to acute ergot toxicity,
including vasospasm and ischaemia (see
section 4.5).
GI motility agent Cisapride Increased plasma concentrations of
cisapride. Thereby, increasing the risk of
serious arrhythmias from this agent (see
section 4.5).
Hepatitis C virus direct Elbasvir/grazoprevir Increased risk of alanine transaminase
acting antivirals (ALT) elevations (see section 4.5).
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylergonovine (HOS-086155) cisapride (HOS-085610) hepatitis C virus (HOS-108813) elbasvir (HOS-108814) grazoprevir (HOS-108815) alanine (HOS-088949) venetoclax (HOS-086143) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) lead (HOS-085592) ergot alkaloids (HOS-108807) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage deedafd686f2a7856b9535fd14424479a75da74b88007e447ddb2a759abcc3fe · Zeichen 2941–6504 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 17–18
HOS-108900 · Präparat HOS-093083
17
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of
colchicine-related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased
risk of adverse events related to
fusidic acid, notably
rhabdomyolysis (see section 4.3).
When used for osteo-articular
infections, where the co-
administration is unavoidable,
close clinical monitoring for
muscular adverse events is
strongly recommended (see section
4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline
(single dose) AUC: ↑ 22% related adverse events, the
Cmax: ↔ combination of bedaquiline and
(Lopinavir/ritonavir Kaletra should be avoided. If the
400/100 mg BID, multiple A more pronounced effect on benefit outweighs the risk,
dose) bedaquiline plasma exposures co-administration of bedaquiline
may be observed during with Kaletra must be done with
prolonged co-administration with caution. More frequent
lopinavir/ritonavir. electrocardiogram monitoring and
monitoring of transaminases is
CYP3A4 inhibition likely due to recommended (see section 4.4 and
lopinavir/ritonavir. refer to the bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f0063cdfed3d4b44f9ebbe33645572935b60d76cab70c9d2b49e5bc05279da2c · Zeichen 30589–35272 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-109013 · Präparat HOS-093083
53
benefit/risk to patient justifies the use
of voriconazole.
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg Cmax: ↑ 1.8-fold with renal and/or hepatic impairment
twice-daily) Due to P-gp and/or CYP3A4 is contraindicated due to a potential
inhibition by ritonavir. increase of colchicine-related serious
and/or life-threatening reactions such
as neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3 and
4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is recommended
in patients with normal renal or
hepatic function if treatment with
Kaletra is required. Refer to
colchicine prescribing information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased risk
of adverse events related to fusidic
acid, notably rhabdomyolysis (see
section 4.3). When used for osteo-
articular infections, where the co-
administration is unavoidable, close
clinical monitoring for muscular
adverse events is strongly
recommended (see section 4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline related
(single dose) AUC: ↑ 22% adverse events, the combination of
Cmax: ↔ bedaquiline and Kaletra should be
(Lopinavir/ritonavir avoided. If the benefit outweighs the
400/100 mg BID, A more pronounced effect on risk, co-administration of bedaquiline
multiple dose) bedaquiline plasma exposures with Kaletra must be done with
may be observed during caution. More frequent
prolonged co-administration with electrocardiogram monitoring and
lopinavir/ritonavir. monitoring of transaminases is
recommended (see section 4.4 and
CYP3A4 inhibition likely due to refer to the bedaquiline SmPC).
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): voriconazole (HOS-084524) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) fusidic acid (HOS-086146) bedaquiline (HOS-086268)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cad5366a6fb47c00b40c65b02f661a2f3f24b27d6187e7ce6cfffb83a5f12fd8 · Zeichen 29746–34245 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89
HOS-109088 · Präparat HOS-093083
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra should
be avoided unless an assessment of
the benefit/risk to patient justifies
the use of voriconazole.
Anti-gout agents:
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of colchicine-
related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trazodone (HOS-086251) ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9043d84be2324d7e08bc16eeeba0c8c1136fbb4075d51aeb08ee163e186d9cab · Zeichen 28361–32171 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-109458 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
12
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) glyburide (HOS-109273) phenytoin (HOS-084531) tolbutamide (HOS-086568) glucose (HOS-088412) fluconazole (HOS-087945) astemizole (HOS-085608) lead (HOS-085592) terfenadine (HOS-085607) indinavir (HOS-084518) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage c43ce720ce152b6ffc284ecb767edcbe81187c3aba91372adac27d1baca516f9 · Zeichen 11584–14886 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 44–45
HOS-109540 · Präparat HOS-093201
44
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) terfenadine (HOS-085607) indinavir (HOS-084518) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f6a70c9142e2f517a32a7e0c09633e6caa907ecd38c03200c8d88f9a5a119b6e · Zeichen 14558–15283 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 76–77
HOS-109604 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
76
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) tolbutamide (HOS-086568) glucose (HOS-088412) glipizide (HOS-109460) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) lead (HOS-085592) terfenadine (HOS-085607) indinavir (HOS-084518) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f19ccc38aa29c7c75168a00762b93a1ec1fb9ac13e31bd781df6a45a736467a1 · Zeichen 11616–14918 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 44
HOS-112157 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ
with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a
narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil, triazolam, orally administered midazolam, lomitapide, and ergot
alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). Co-administration of
REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed-dose
combination is contraindicated because of the increase in grazoprevir and elbasvir plasma
concentrations and potential for the increase in risk of ALT elevations associated with increased
grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in
the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma
concentrations (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bepridil (HOS-085612) triazolam (HOS-086168) midazolam (HOS-086167) lomitapide (HOS-086160) ergotamine (HOS-086154) dihydroergotamine (HOS-086152) elbasvir (HOS-108814) grazoprevir (HOS-108815) glecaprevir (HOS-086297) pibrentasvir (HOS-086298) ritonavir (HOS-084521) quetiapine (HOS-086150) lurasidone (HOS-086148) alfuzosin (HOS-086139) astemizole (HOS-085608) terfenadine (HOS-085607) cisapride (HOS-085610) pimozide (HOS-085600) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8c472f02d161fbf877b321685a02acd6721db094612098433562a9a244834b35 · Zeichen 315–1385 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114797 · Präparat HOS-094169
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent
on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone,
bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as
dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such
as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics
(such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as
simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist
alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition,
co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly
dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and
metoprolol given in heart failure (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) lurasidone (HOS-086148) midazolam (HOS-086167) triazolam (HOS-086168) simvastatin (HOS-086158) lovastatin (HOS-086157) alfuzosin (HOS-086139) sildenafil (HOS-086162) flecainide (HOS-086203) propafenone (HOS-084530) metoprolol (HOS-090094) pimozide (HOS-085600) sertindole (HOS-085601) ritonavir (HOS-084521) amiodarone (HOS-085596) bepridil (HOS-085612) quinidine (HOS-085593) astemizole (HOS-085608) terfenadine (HOS-085607) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 20
HOS-114845 · Präparat HOS-094169
Inhibition of CYP 2D6
by tipranavir/r
Antihistamines
Astemizole Based on theoretical The concomitant use of Aptivus,
Terfenadine considerations, tipranavir, co- co-administered with low dose
No interaction study administered with low dose ritonavir, with astemizole or
performed ritonavir, is expected to increase terfenadine is contraindicated due
astemizole and terfenadine to potential serious and/or life
concentrations. threatening events (see
section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Ergot derivatives
Dihydroergotamine Based on theoretical The concomitant use of Aptivus,
Ergonovine considerations, tipranavir, co- co-administered with low dose
Ergotamine administered with low dose ritonavir, with
Methylergonovine ritonavir, is expected to increase dihydroergotamine, ergonovine,
No interaction study dihydroergotamine, ergonovine, ergotamine or methylergonovine
performed ergotamine and is contraindicated due to potential
methylergonovine concentrations. serious and/or life threatening
events (see section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Gastrointestinal motility agents
Cisapride Based on theoretical The concomitant use of Aptivus,
No interaction study considerations, tipranavir, co- co-administered with low dose
performed administered with low dose ritonavir, with cisapride is
ritonavir, is expected to increase contraindicated due to potential
cisapride concentrations. serious and/or life threatening
events (see section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dihydroergotamine (HOS-086152) ergonovine (HOS-086153) astemizole (HOS-085608) terfenadine (HOS-085607) ritonavir (HOS-084521) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 0bc47b611eec8274771aaf2f47f7c4c8b088648012f479c3407b7ce6fe3032f6 · Zeichen 50501–52945 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranolazine (HOS-086141) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601) triazolam (HOS-086168) midazolam (HOS-086167) sildenafil (HOS-086162) avanafil (HOS-086161) simvastatin (HOS-086158) lovastatin (HOS-086157) lomitapide (HOS-086160) ticagrelor (HOS-112065) ritonavir (HOS-084521) cobicistat (HOS-088111) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) quinidine (HOS-085593) ranolazine (HOS-086141) ritonavir (HOS-084521) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601) triazolam (HOS-086168) midazolam (HOS-086167) sildenafil (HOS-086162) avanafil (HOS-086161) simvastatin (HOS-086158) lovastatin (HOS-086157) lomitapide (HOS-086160) ticagrelor (HOS-112065)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 87
HOS-116580 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) grazoprevir (HOS-108815) ergotamine (HOS-086154) methylergonovine (HOS-086155) ritonavir (HOS-084521) cobicistat (HOS-088111) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) quinidine (HOS-085593) ranolazine (HOS-086141) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) cisapride (HOS-085610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 986882b0b712a9a949916f43fb05836de98ea933859327e753cd9346903445da · Zeichen 1383–2254 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 13–14
HOS-130949 · Präparat HOS-096981
13
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUCτ ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUCτ ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): terfenadine (HOS-085607) lead (HOS-085592) indinavir (HOS-084518) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage ec40d0541dc5a9facbabb829b9ee0950b5412f1a75a9264890b523b74f07c466 · Zeichen 14461–15186 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.